HE3286: A novel synthetic steroid as an oral treatment for autoimmune disease

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 781-790

  Ahlem, C ^a   Auci, D ^a   Mangano, K ^b   Reading, C ^a   Frincke, J ^a   Stickney, D ^a   Nicoletti, F ^b  

^a HollisEden Pharmaceuticals   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Androstenetriol; Arthritis; DHEA; Multiple sclerosis; Ulcerative colitis

Indexed keywords

17ALPHA ETHYNYL 5 ANDROSTENE 3BETA 7BETA 17BETA TRIOL; 5 ANDROSTENE 3BETA 7BETA 17BETA TRIOL; ANTIINFLAMMATORY AGENT; COLLAGEN; COLLAGEN ANTIBODY; FULVESTRANT; HE 3286; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIVER RECEPTOR HOMOLOG 1; PERTUSSIS TOXIN; PROTEOLIPID PROTEIN; SALAZOSULFAPYRIDINE; STROMELYSIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; BODY WEIGHT; CLINICAL FEATURE; CLINICAL TRIAL; COLLAGEN ANTIBODY INDUCED ARTHRITIS; COLLAGEN INDUCED ARTHRITIS; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RAT; STEROID ANALYSIS; SWISS JAMES LAMBERT MOUSE; TREATMENT DURATION; ULCERATIVE COLITIS; WISTAR RAT;

EID: 70049110871     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04798.x     Document Type: Conference Paper

References (27)

1. Kuek, A., B.L. Hazleman & A.J. Ostor. 2007. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad. Med. J. 83: 251-260.
2. Wislowska, M. & D. Jakubicz. 2007. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatol. Int. 27: 641-647.
3. Sandborn, W.J. & S.B. Hanauer. 1999. Antitu-mor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 5: 119-133.
4. Webb, S.J. et al. 2006. The biological actions of dehy-droepiandrosterone involves multiple receptors. Drug Metab. Rev. 38: 89-116.
5. Svec, F. & J.R. Porter. 1998. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc. Soc. Exp. Biol. Med. 218: 174-191.
6. Auci, D.L. et al. 2003. The immunobiology and therapeutic potential of androstene hormones and their synthetic derivatives: novel anti-inflammatory and immune regulating steroid hormones. Mod. Asp. Im-munobiol. 3: 64-70.
7. Giltay, E.J. et al. 1998. Effects of dehydroepiandros-terone administration on disease activity in patients with rheumatoid arthritis [letter]. Br. J. Rheumatol. 37: 705-706.
8. Sirrs, S.M. & R.A. Bebb. 1999. DHEA: panacea or snake oil? Can. Fam. Phys. 45: 1723-1728.
9. van Vollenhoven, R.F. et al. 1999. A double-blind, placebo-controlled, clinical trial of dehy-droepiandrosterone in severe systemic lupus erythe-matosus [see comments]. Lupus 8: 181-187.
10. Fitzpatrick, J.L. et al. 2001. Metabolism of DHEA by cytochromes P450 in rat and human liver mi-crosomal fractions. Arch. Biochem. Biophys. 389: 278-287.
11. Leblanc, M. et al. 2003. Bioavailability and phar-macokinetics of dehydroepiandrosterone in the cynomolgus monkey. J. Clin. Endocrinol. Metab. 88: 4293-4302.
12. Buster, J.E. et al. 1992. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. Am. J. Obstet. Gynecol. 166: 1163-1168; discussion 1168-1170.
13. Marwah, A., P. Marwah & H. Lardy. 2002. Ergos-teroids. VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. J. Chromatogr. B Biomed. Sci. Appl. 767: 285-299.
14. Loria, R.M. & D.A. Padgett. 1992. Androstenediol regulates systemic resistance against lethal infections in mice. Arch. Virol. 127: 103-115.
15. Loria, R.M. 2002. Immune up-regulation and tumor apoptosis by androstene steroids. Steroids 67: 953-966.
16. Loria, R.M., D.A. Padgett & P.N. Huynh. 1996. Regulation of the immune response by dehy-droepiandrosterone and its metabolites. J. E n d o c r i n o l . 150(Suppl): S209-S220.
17. Le Mee, S. et al. 2008. 7beta-Hydroxy-epiandrosterone-mediated regulation of the prost-aglandin synthesis pathway in human peripheral blood monocytes. Steroids 73: 1148-1159.
18. Hennebert, O. et al. 2008. Anti-inflammatory effects and changes in prostaglandin patterns induced by 7beta-hydroxy-epiandrosterone in rats with colitis. J. Steroid Biochem. Mol. Biol. 110: 255-262.
19. Hill, M. et al. 2005. The identification and simultaneous quantification of 7-hydroxylated metabolites of pregnenolone, dehydroepiandrosterone, 3beta, 17beta-androstenediol, and testosterone in human serum using gas chromatography-mass spec-trometry. J. Steroid Biochem. Mol. Biol. 96: 187-200.
20. Offner, H. et al. 2002. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. J. Neuroimmunol. 130: 128.
21. St Louis, J. et al. 2001. Tolerance induction by acylated peptides: suppression of EAE in the mouse with palmitoylated PLP peptides. J. Neuroimmunol. 115: 79-90.
22. Suzuki, T. et al. 1991. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin. Immunol. Immunopathol. 61: 202-211.
23. Suzuki, N., T. Suzuki & T. Sakane. 1996. Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus. Ann. Med. Interne. (Paris) 147: 248-252.
24. Auci, D. et al. 2007. A new orally bioavailable syntheic androstene inhibits collagen-induced arthritis in the mouse. Ann. N. Y. Acad. Sci. 1110: 630-640.
25. Bebo, B.F. Jr. et al. 2001. Low-dose estrogen therapy ameliorates experimental autoimmune en-cephalomyelitis in two different inbred mouse strains. J. Immunol. 166: 2080-2089.
26. Brasier, A.R. 2006. The NF-kappaB regulatory network. Cardiovasc. Toxicol. 6: 111-130.
27. Auci, D.L., C.L. Reading & J.M. Frincke. 2009. 7-Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases. Autoimmun. Rev. 8: 369-372.